2023年、2024年及2025年上半年，艾米森生命分别实现营业收入623.3万元、723.8万元、651.3万元；分 别实现净利润-6792.2万元、-3863万元和-1390.6万元。公司收入基本来自销售已获国家药监局批准的产 品，即艾长康、艾长健、艾思宁及艾馨甘。 2023年、2024年及2025年上半年，公司研发开支分别为0.23亿元、0.15亿元及0.045亿元。 招股书显示，募集资金将用于：公司核心产品艾馨甘及艾光乐的研发、注册备案及商业化；公司多款管 线产品的研发、注册备案及商业化；提高一般研发能力及提升技术；加强生产设施的自动化；通过潜在 收购或授权引进癌症检测领域的候选产品，持续扩大及多元化公司的产品组合；公司的营运资本及其他 一般企业用途。 将继续依赖有限数量客户 9月28日，武汉艾米森生命科技股份有限公司(简称"艾米森生命")向港交所递交上市申请。 艾米森生命于2015年1月成立，是一家早期癌症检测公司。2023年、2024年及2025年上半年，公司分别 实现净利润-6792.2万元、-3863万元和-1390.6万元。 深耕肿瘤分子检测市场 根据招股书，艾米森生命深耕肿瘤分子检测市场。 ...

Core Insights - The announcement of the completion of the ETHK building marks a significant milestone for the company as it transitions to a new strategic focus on blockchain technology and compliance in the financial ecosystem [4][5][8] - The new logo symbolizes the company's evolution into a builder of next-generation on-chain financial ecosystems, moving beyond its previous identity [4][8] Group 1: ETHK Building and Its Significance - The ETHK building is the world's first core base dedicated to the research and ecological empowerment of Real World Assets (RWA) digitalization technology, located in Nanjing with a total area of approximately 70,000 square meters [5][7] - The building serves a dual purpose: as a physical infrastructure for research and collaboration, and as a credible technology development and output center, expected to gather over 5,000 technical experts and engineers [7][8] - Nanjing was chosen for its strategic alignment with the company's focus on high-tech intellectual property asset digitalization and its proximity to top universities, providing talent support [7][8] Group 2: RWA Ecosystem and Strategic Transformation - The logo update and building completion represent the company's "second entrepreneurship," fully transitioning to the RWA sector, which involves the tokenization of real-world assets [8][9] - The RWA market is projected to grow significantly, with a total locked value expected to reach $12.5 billion by June 2025, a 124% increase from 2024 [8][9] - The company has established ETHK Inc. and ETHK HOLDINGS LIMITED to position itself as a technology driver and infrastructure provider in the RWA ecosystem [8][9] Group 3: Strategic Partnerships and Business Model Innovation - The company announced a strategic partnership with Renhe Pharmaceutical to establish the world's first OTC vertical RWA exchange in the U.S., marking a key case for its "exchange within an exchange" business model [9][10] - This innovative model aims to provide on-chain financial infrastructure for leading enterprises across various industries, facilitating the creation of vertical RWA exchanges [10] - The partnership is expected to enhance both parties' capabilities, enabling the internationalization of Chinese assets and the introduction of innovative OTC products from abroad [10][11] Group 4: Value Creation and Market Potential - The company's RWA strategy aims to create multidimensional value, emphasizing altruistic values and contributing to national strategies and public welfare [11][12] - The collaboration with Renhe Pharmaceutical is set to revolutionize the OTC industry by enhancing innovation efficiency across the entire value chain [11][12] - The RWA market is on the verge of significant growth, with major financial institutions entering the space, positioning the company to lead in this emerging sector [12][13]

Core Viewpoint - The Jinan Precision Medicine Industrial Park is rapidly developing as a key component of the Jinan International Medical Center, providing essential infrastructure and comprehensive services to help resident companies overcome development bottlenecks and achieve rapid transformation of technological achievements [1][2]. Group 1: Company Development - Jinan Huayin Kang Medical Testing Co., Ltd. focuses on third-party medical diagnostic services and has initiated a remote pathology platform project to convert traditional glass pathology slices into digital images, enabling remote diagnosis for grassroots hospitals [1][2]. - Shandong Aopeng Intelligent Technology Co., Ltd. has achieved a significant breakthrough with its self-developed intelligent robot successfully completing an all-automated interventional surgery animal experiment, demonstrating sub-millimeter operational precision [2][3]. Group 2: Market Opportunities and Challenges - The Precision Medicine Industrial Park has facilitated the development of resident companies by coordinating support and policy assistance, leading to a 10% increase in the budget for Jinan Huayin Kang this year compared to last year [2]. - The park has organized product promotion events and established communication channels with clinical experts, which are crucial for accelerating product iteration and market entry for companies like Aopeng Intelligent [3]. Group 3: Growth Metrics - The number of registered and resident companies in the Jinan Precision Medicine Industrial Park has increased by 248% and 300% respectively this year, indicating a significant improvement in both quantity and quality of enterprises [3]. - The park focuses on providing tailored services to different types of companies, including high-end medical services, new-generation biotechnology, high-end medical devices, and digital healthcare, covering nearly 20 sub-sectors [3][4]. Group 4: Strategic Development - The park is forming a comprehensive medical industry chain with upstream and downstream connections, focusing on new areas such as cell and gene therapy, brain-machine interfaces, and AI healthcare [4]. - By creating public technology platforms and integrating market resources, the park is enhancing its "precision" role and effectiveness, becoming a vital engine for the high-quality development of the Jinan International Medical Center [4].

Core Viewpoint - Huajian Medical is undergoing a strategic transformation from a medical enterprise to a builder of a blockchain-based financial ecosystem, marking a significant shift in its business focus towards digital industry technology infrastructure [4][5]. Group 1: Strategic Transformation - The company has announced a partnership with ETHK Group to establish two new companies, ETHK Inc and ETHK HOLDINGS LIMITED, focusing on decentralized financial platforms and digital industry investments [1][4]. - The rebranding reflects this shift, changing its English name from "IVD Medical Holding Limited" to "ETHK Labs Inc." and its Chinese name to "华检数字产业集团有限公司" [1][4]. - The new strategy aims to create a safe, efficient, compliant, and open decentralized financial platform under the "ETHK" brand [4]. Group 2: Global Asset Empowerment - The ETHK ecosystem is designed to facilitate the globalization of Chinese assets, providing a one-stop investment platform for global capital [6]. - The strategic framework includes five pillars: robust technical infrastructure, diverse financial products, sustainable business models, global compliance frameworks, and seamless user experiences [6]. - This approach addresses key pain points in the globalization of Chinese assets, such as limited financing channels and low cross-border flow efficiency [6]. Group 3: Financial Infrastructure for National Benefit - The strategic upgrade aligns with national policies promoting the marketization of intellectual property and innovation in technology finance [7]. - The ETHK strategy is positioned to enhance the international pricing power of Chinese assets and support the internationalization of the Renminbi [9]. - Market data indicates a significant growth potential in the tokenized asset market, with predictions of a global market size reaching $16.1 trillion by 2030 [7]. Group 4: Value Creation Paradigm - The new positioning reflects a thoughtful strategic choice, aiming to create value for various stakeholders, including the nation, industry, society, and investors [9]. - The ETHK ecosystem lowers the barriers for asset digitization, providing new financing avenues for high-tech enterprises and promoting inclusive finance [9]. - The company's stock performance has shown strong investor support, with shares rising from HKD 2 to HKD 10.44 since July, indicating confidence in the strategic direction [8].

■本报记者 王爱静 往前追溯，今年7月份，中国人民银行浙江省分行牵头印发《关于推动金融机构做好联动支持科技型企 业融资服务工作的指导意见》，探索创新"浙科联合贷"服务模式，以信息共享、风险共担、资源互补、 政策集成"四位一体"为核心，旨在疏导解决局限科技金融的堵点痛点，破解单一银行信贷支持难以匹配 科技型企业全生命周期融资需求的难题，形成银行联合支持科技型企业融资的新探索，为企业提供更具 耐心的贷款服务。自"浙科联合贷"政策推出以来，浙江政银企三方迅速协同联动，将"浙科联合贷"服务 模式细化为可操作、可落地的工作机制。短短数周，首批项目便在杭州科创金融改革试验区内"开花结 果"，精准匹配科技型企业不同阶段融资需求。 "为更好满足科技型企业全生命周期融资需求，围绕科技型企业初创期、成长期、成熟期三个成长阶 段，我们分别设计了'浙科普惠联合贷''浙科成长联合贷''浙科领航联合贷'等专项产品。"中国人民银行 浙江省分行相关负责人表示。 "我们这样的创新型企业，前期研发投入非常大，如果没有政策的支持很难走到今天。"杭州汇萃智能科 技有限公司董事长周才健向记者介绍。 杭州汇萃智能科技有限公司是一家机器视觉软硬件产品及解 ...

Core Viewpoint - The article highlights the launch of David's innovative red-blue dual-color early pregnancy detection technology at the "China Health Industry (International) Ecological Conference," emphasizing the growing demand for family health management products in response to national policies promoting a family-friendly society and optimizing population structure [1]. Group 1: Innovation and Technology - David's new pregnancy test significantly improves detection limits compared to traditional products, allowing for earlier awareness of pregnancy [8]. - The patented red-blue dual-color technology enhances result visualization, providing a scientific basis for pregnancy management [8]. Group 2: Cultural Integration - David integrates Eastern cultural elements into product design, transforming medical testing tools into carriers of "good pregnancy" blessings, reflecting deep insights into user needs and humanistic care [11]. Group 3: Market Position and Product Range - Since its establishment in 2001, David has focused on rapid diagnostic biology, with its 2004 colloidal gold early pregnancy test strip becoming a benchmark product in the market [13]. - David has expanded its product matrix to cover various health areas, including ectopic pregnancy, HIV, gonorrhea, syphilis, and influenza, reinforcing its industry-leading position [13]. Group 4: Industry Impact - The launch of David's red-blue dual-color early pregnancy detection technology and new products sets a new standard in the family self-testing health product market, combining technology, culture, and service [17]. - As a core brand under Yikangnas, David aims to deliver high-quality health testing products conveniently to consumers, invigorating the family health market in the new retail era [17].

Group 1: Transaction Details - On September 1, 2025, Huajian Medical announced the acquisition of a 20.31% stake in Guofu Quantum for HKD 3.142 billion, becoming the controlling shareholder of the quantum technology company [1][2] - The acquisition involves the issuance of approximately 324 million shares at a price of about HKD 9.69 per share [2] Group 2: Strategic Synergy - The acquisition represents a strategic collaboration between Huajian Medical and Guofu Quantum, enhancing Huajian's capabilities in the digital asset and RWA sectors [6][7] - Huajian Medical aims to create a complete ecosystem for the tokenization of medical innovation assets and high-tech assets of publicly listed companies [8][9] Group 3: Market Context and Growth Potential - The RWA trading platform developed by Huajian Medical is designed to improve liquidity and reduce financing costs for high-value medical assets, which are characterized by long development cycles and low liquidity [9] - The total transaction amount for innovative drugs in China reached USD 60.8 billion in the first half of 2025, reflecting a 129% year-on-year increase, indicating growing recognition of Chinese innovative drug assets in the global market [9] Group 4: Policy Support - The strategic layout of Huajian Medical and Guofu Quantum aligns with national policy directions aimed at promoting the global market development of innovative drugs [10] - Recent regulatory advancements in Hong Kong regarding stablecoins and digital assets provide a favorable environment for the development of RWA business [10] Group 5: Challenges and Future Outlook - Despite the promising outlook for RWA, challenges such as liquidity issues and regulatory complexities remain [11] - The RWA industry is transitioning from concept validation to large-scale application, with a total locked value (TVL) reaching USD 12.5 billion as of June 2025, indicating significant growth potential [12]

Group 1 - The core point of the news is that Huajian Medical has acquired a 20.31% stake in Guofu Quantum for HKD 3.142 billion, becoming the controlling shareholder, which is a strategic move to build a global RWA tokenized digital trading platform [1][2][7] - The acquisition involves Huajian Medical's subsidiary issuing approximately 324 million shares at around HKD 9.69 per share to complete the purchase [2] - This acquisition is seen as a significant step for Huajian Medical, which has shifted from being a medical equipment distributor to actively pursuing blockchain strategies, including the establishment of the world's first RWA trading platform for innovative drug intellectual property [5][8] Group 2 - The strategic collaboration between Huajian Medical and Guofu Quantum is expected to create a complete ecosystem for the tokenization of medical innovation drug intellectual property and high-tech assets of publicly listed companies [8][9] - Guofu Quantum, holding multiple financial licenses, enhances Huajian Medical's capabilities in the digital asset and RWA sectors, while Huajian Medical provides financial support and resources from the medical industry [6][8] - The RWA trading platform developed by Huajian Medical aims to connect real-world assets with global capital, potentially positioning the company as a dominant player in the RWA sector, similar to Alibaba's role in connecting SMEs with global markets [9][10] Group 3 - The strategic initiatives align with national policies promoting the global market development of innovative drugs, supported by recent regulatory advancements in digital asset management in Hong Kong and the U.S. [10] - The RWA market is experiencing significant growth, with a total locked value (TVL) reaching USD 12.5 billion by mid-2025, indicating a strong upward trend in asset tokenization [12] - Despite the promising outlook, challenges such as liquidity issues and regulatory complexities remain critical factors for the RWA market's development [11]

Core Insights - ICL industry is facing challenges, but ICL Holdings has shown strong growth with a significant increase in bid amounts by 106% year-on-year, outperforming industry averages [1][3] - The company reported a revenue of approximately 1.27 billion RMB, maintaining a stable performance amidst a market where many peers experienced over 20% revenue decline [2] - ICL Holdings has diversified its business structure and improved operational efficiency, which has contributed to its resilience and growth [2][4] Business Performance - The company's co-construction business revenue grew by 30% year-on-year, achieving a historical high with a compound annual growth rate of 48% over the past four years [2] - The CRO business also performed strongly, with an 18% year-on-year revenue increase, capturing over 50% market share in the NASH segment [3] - The company has successfully expanded its market presence, with a 51% increase in the number of bids won [3] Cost Management - ICL Holdings has implemented lean management practices, resulting in a nearly 13% decrease in reagent procurement costs and a 4% reduction in logistics costs per sample [4] - The company has improved operational efficiency, with clinical and pathological personnel productivity increasing by 11% and 6%, respectively [4] AI and Digital Transformation - The company is at the forefront of integrating AI into its medical services, with AI-assisted diagnosis technology achieving efficiency rates of 6-7 times that of human performance [5][6] - ICL Holdings has launched an intelligent assistant, "Ai Xiao Yi," providing comprehensive services to doctors, enhancing the doctor-patient experience [6] - The company is advancing its digital infrastructure, with a new LIMS system operational in 32 subsidiaries and plans for full coverage by the end of the year [6][7] Strategic Outlook - ICL Holdings has outlined a five-year growth plan focusing on various growth paths, including deepening customer development in the routine testing segment and accelerating business expansion in the CRO segment [8] - The company aims to leverage mergers and acquisitions to enhance resource integration and collaboration across its business segments [8] - Given its strong fundamentals and market position, ICL Holdings is positioned as a promising investment opportunity in the healthcare sector [8]

Group 1 - Genalive Medical Company is a joint venture in which BGI Almanahil Health for Medical Services holds a 50% stake, and it is a wholly-owned subsidiary of BGI Almanahil in Saudi Arabia [1] - On August 21, 2025, BGI Almanahil and Genalive signed a capital increase agreement to raise 44 million Saudi Riyals (approximately 84 million RMB) to support business development [1] - Following the capital increase, Genalive's registered capital will rise from 90.5 million Saudi Riyals to 134.5 million Saudi Riyals, with BGI Almanahil maintaining its 50% ownership stake [1] Group 2 - Genalive won a public hospital three-year outsourcing testing service procurement project worth approximately 950 million RMB from NUPCO in March 2025 [2] - The capital increase aims to ensure Genalive's operational funding needs for the awarded project, enhance its comprehensive business capabilities, and strengthen strategic collaboration with BGI Almanahil [2] - This move aligns with the company's long-term overseas business development strategy and aims to expand its leading position in Saudi Arabia and the Gulf region [2]